| |
||
|
Catalogue Number |
Product | Order number / Unit |
| |
||
| 3750 | CPTPX |
3750.0010: 10 mg per vial
Please inquire for customized filling and bulk quantities.
|
|
Precursor for [18F]CPFPX
8-Cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine |
||
| Molar Mass: 588.72 | ||
| C29H40N4O7S | ||
| [478173-67-0] | ||
| Colourless solid packaged in dark glass vials. | ||
| Purity: > 95 % | ||
|
Certificates:
CoA; 1H NMR spectrum |
||
|
Chemical Name: CA index name: Propanoic acid, 2,2-dimethyl-, [8-cyclopentyl-1,2,3,6-tetrahydro-3-[3-[[(4-methylphenyl)sulfonyl]oxy]propyl]-2,6-dioxo-1-propyl-7H-purin-7-yl]methyl ester |
||
|
Synonymes: 2,2-Dimethyl-propionic acid 8-cyclopentyl-2,6-dioxo-1-propyl-3-[3-(toluene-4-sulfonyloxy)-propyl]-1,2,3,6-tetrahydro-purin-7-ylmethyl ester; 8-Cyclopentyl-3-(3-tosyloxypropyl)-7-pivaloyloxymethyl-1-propylxanthine |
||
|
Literature: Holschbach M. H. et al. Synthesis and Evaluation of No-Carrier-Added 8-Cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine ([18F]CPFPX): A Potent and Selective A1-Adenosine Receptor Antagonist for in Vivo Imaging. J. Med. Chem. 2002, 45, 5150-5156. |
||
| Bauer A. et al. Evaluation of 18F-CPFPX, a Novel Adenosine A1 Receptor Ligand: In Vitro Autoradiography and High-Resolution Small Animal PET. J. Nucl. Med. 2003, 44, 1682-1689. | ||
| Matusch A. et al. Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Nucl. Med. Biol. 2006, 33, 891-898. | ||
| Elmenhorst D. et al. Caffeine Occupancy of Human Cerebral A1 Adenosine Receptors: In Vivo Quantification with 18F-CPFPX and PET. J. Nucl. Med. 2012, 53, 1723-1729. | ||
| date of product catalogue issue: 10 May 2017 | ||